Sugi Predict

Sugi Predict / Compounds / SCHEMBL4122735

SCHEMBL4122735

SCHEMBL4122735

O=C(O)c1ccc(-n2ccc(C(F)(F)F)n2)cc1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 5/20 0.62
▸ MAPT P10636 4/20 0.62
▸ RAB9A P51151 4/20 0.62
▸ POLB P06746 1/20 0.55
▸ NPSR1 Q6W5P4 3/20 0.50
▸ MAPK1 P28482 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ PAX8 Q06710 1/20 0.49
▸ MGLL Q99685 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ PTGS2 P35354 1/20 0.45
▸ KMT2A Q03164 1/20 0.44
▸ F10 P00742 1/20 0.43
▸ UBE2N P61088 1/20 0.42
▸ SRD5A2 P31213 1/20 0.42
▸ CYP2C9 P11712 1/20 0.41
▸ ADH5 P11766 1/20 0.40
▸ MAOA P21397 1/20 0.40
▸ MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6022548 0.86 NPC1 (0.57) NPC1MAPTRAB9APOLBNPSR1
SCHEMBL12824117 0.86 NPC1 (0.57) NPC1MAPTRAB9APOLBNPSR1
SCHEMBL1039420 0.86 NPC1 (0.57) NPC1MAPTRAB9APOLBNPSR1
SCHEMBL21815958 0.82 NPC1 (0.53) NPC1MAPTRAB9APOLBNPSR1
SCHEMBL31133351 0.82 NPC1 (0.53) NPC1MAPTRAB9APOLBNPSR1
SCHEMBL28845512 0.81 MAPT (0.57) NPC1MAPTRAB9APOLBNPSR1
SCHEMBL12804825 0.80 NPC1 (0.56) NPC1MAPTRAB9APOLBNPSR1
SCHEMBL1094013 0.79 NPC1 (0.63) NPC1MAPTRAB9APOLBNPSR1
SCHEMBL287239 0.79 NPC1 (0.53) NPC1MAPTRAB9APOLBNPSR1
SCHEMBL30991450 0.79 PDE3B (0.47) NPC1MAPTRAB9APOLBNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-05-13 — — US disclosed
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-04-08 — — US disclosed
US-20240360155-A1 Benzodiazepine Derivatives as RSV Inhibitors ENANTA PHARM INC (US) 2024-10-31 — — US disclosed
US-11952389-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2024-04-09 — — US disclosed
EP-3687543-B1 COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS ENANTA PHARM INC (US) 2024-03-20 — — EP disclosed
CN-111386118-B Combination pharmaceutical agents as RSV inhibitors 英安塔制药有限公司 2023-05-09 — — CN disclosed
US-20230087410-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARM INC (US) 2023-03-23 — — US disclosed
US-20220323460-A1 COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS ENANTA PHARM INC (US) 2022-10-13 — — US disclosed
US-11390631-B1 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2022-07-19 — — US disclosed
US-11390610-B2 Piperazine derivatives as MAGL inhibitors HOFFMANN-LA ROCHE INC. (US) 2022-07-19 — — US disclosed
WO-2005100321-A1 PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-10-27 — — WO disclosed
CN-1183134-C Tricyclic vasopressin agonists — 2005-01-05 — — CN disclosed
US-6831079-B1 Oral delivery; nitrogen triheterocyclic active material, surfactant, polyethylene glycol with sucrose fatty acid esters and/or polyvinylpyrrolidone AMERICAN CYANAMID COMPANY 2004-12-14 — — US disclosed
EP-1000062-B1 TRICYCLIC VASOPRESSIN AGONISTS WYETH CORP (US) 2004-09-22 — — EP disclosed
US-6511974-B1 Non-peptidic and have good oral bioavailability, specific vasopressin V2 agonists, therefore do not raise blood pressure WYETH 2003-01-28 — — US disclosed
EP-1216045-A2 VASOPRESSIN AGONIST FORMULATION AND PROCESS American Cynamid Company (US) 2002-06-26 — — EP disclosed
WO-2001022969-A2 VASOPRESSIN AGONIST FORMULATION AND PROCESS AMERICAN CYNAMID COMPANY (US) 2001-04-05 — — WO disclosed
CN-1272111-A Tricyclic vasopressin agonists AMERICAN HOME PROD (US) 2000-11-01 — — CN disclosed
EP-1000062-A1 TRICYCLIC VASOPRESSIN AGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-05-17 — — EP disclosed
WO-1999006409-A1 TRICYCLIC VASOPRESSIN AGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 1999-02-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360155-A1 Benzodiazepine Derivatives as RSV Inhibitors GABRA5, GABRA1, GABBR2 NPC1 224/4885MAPT 2157/4885RAB9A 1384/4885
US-11952389-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 NPC1 224/4885MAPT 2157/4885RAB9A 1384/4885
US-11390631-B1 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 NPC1 224/4885MAPT 2157/4885RAB9A 1384/4885
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 NPC1 224/4885MAPT 2157/4885RAB9A 1384/4885
US-11390610-B2 Piperazine derivatives as MAGL inhibitors MAGI3, PYM1, MAG NPC1 509/4885MAPT 1294/4885RAB9A 361/4885
US-20220323460-A1 COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS SERPINB1, FURIN, HIF1AN NPC1 480/4885MAPT 3417/4885RAB9A 704/4885
US-20230087410-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS GABRA5, GABRA1, GABBR2 NPC1 224/4885MAPT 2157/4885RAB9A 1384/4885
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ACE, ACE2, SPCS3 NPC1 399/4885MAPT 2865/4885RAB9A 384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.